This article has Open Peer Review reports available.
A simple computer program for calculating PSA recurrence in prostate cancer patients
© Liao and Datta; licensee BioMed Central Ltd. 2004
Received: 03 March 2004
Accepted: 19 June 2004
Published: 19 June 2004
Prostate cancer is the most common tumor in men. The most commonly used diagnostic and tumor recurrence marker is Prostate Specific Antigen (PSA). After surgical removal or radiation treatment, PSA levels drop (PSA nadir) and subsequent elevated or increased PSA levels are indicative of recurrent disease (PSA recurrence). For clinical follow-up and local care PSA nadir and recurrence is often hand calculated for patients, which can result in the application of heterogeneous criteria. For large datasets of prostate cancer patients used in clinical studies PSA measurements are used as surrogate measures of disease progression. In these datasets a method to measure PSA recurrence is needed for the subsequent analysis of outcomes data and as such need to be applied in a uniform and reproducible manner. This method needs to be simple and reproducible, and based on known aspects of PSA biology.
We have created a simple Perl-based algorithm for the calculation of post-treatment PSA outcomes results based on the initial PSA and multiple PSA values obtained after treatment. The algorithm tracks the post-surgical PSA nadir and if present, subsequent PSA recurrence. Times to PSA recurrence or recurrence free intervals are supplied in months.
Use of the algorithm is demonstrated with a sample dataset from prostate cancer patients. The results are compared with hand-annotated PSA recurrence analysis. The strengths and limitations are discussed.
The use of this simple PSA algorithm allows for the standardized analysis of PSA recurrence in large datasets of patients who have undergone treatment for prostate cancer. The script is freely available, and easily modifiable for desired user parameters and improvements.
Prostate cancer is the most common tumor in men and accounts for 41% of male new cancer diagnoses and 14% of cancer deaths. This tumor is predominantly found in older males and thus most studies of prostate cancer progression have been confounded by age-related death not attributable to prostate cancer. For this reason tumor markers for prostate cancer are of utmost importance in estimating death from disease. Prostate cancers arise from the epithelial component of the prostate, a cell that secretes a protein called Prostate Specific Antigen (PSA). This protein is present within prostatic epithelial cells and is secreted in seminal fluid. In addition, prostatic carcinomas release PSA, which is taken up into the blood stream. Thus PSA can be measured in the blood of patients and has been used as an effective screening marker for the development of prostate carcinoma in men. Levels of PSA in the blood drop to less than measurable levels (PSA nadir) after surgical removal of the prostate (radical prostatectomy) or treatment of prostate cancer by radiation [3–5]. This reduction of the PSA blood levels can be tracked over time in men, and the finding of increasing levels of serum PSA is considered evidence of a clinical recurrence of prostate cancer (PSA recurrence), thus triggering additional treatment. These values often predate the clinical evidence of prostate cancer recurrence as determined by radiographic or physical examination, and often are the only initial evidence of prostate tumor progression. Thus trends or changes in prostate specific antigen expression over time can be used as a surrogate marker for prostate cancer related morbidity in clinical studies. This is of particular value due to the protracted course of prostate cancer and the current development of chemotherapeutic, radiotheraputic, cryotheraputic, or nutritional interventions designed to delay the course of disease. For these reasons it is very important to be able to accurately predict and identify trends in the serum PSA levels. Yet in most clinical studies and local treatment decisions PSA nadir and recurrence are hand calculated. This often results in a heterogeneous application of PSA nadir and recurrence guidelines, providing a confounding variable for subsequent use of the data in clinical studies. Thus there is a need for processes that allow for the uniform application of PSA nadir and recurrence criteria that can subsequently be used in clinical studies. Here we present a simple Perl script that can be used with patient data for the determination of PSA nadir and recurrence in men who have been treated for prostate cancer. This algorithm orders the serum PSA values within a data set by date, determines the rate of decrease and the post-treatment disappearance of serum PSA (PSA nadir) based on the PSA half-life, and subsequently identifies increases in serum PSA (PSA recurrence). Timelines are calculated from the PSA nadir in months recurrence free or months to PSA recurrence. The clinical standards and practice guidelines used to determine the rules of the algorithm are described, but can be freely and easily modified by the user. The algorithm is demonstrated using a sample prostate cancer dataset.
The PSA script takes a series of dated PSA values and calculates the PSA drop based on the half-life of PSA in serum to determine PSA nadir. The time to PSA nadir is determined based on the "initial PSA", defined as a PSA value prior to patient treatment, and an estimated PSA half-life of 2–3 days. If PSA nadir is achieved the script subsequently calculates the PSA recurrence, if present, based on sequential rising PSA values and threshold cutoffs. Requirements for evaluation by the PSA script include the initial dated PSA value prior to treatment, the date of initial treatment, and PSA values after radical prostatectomy with their associated dates of testing. With post-treatment PSA values the script will attempt to determine a PSA nadir (see below) or post the samples as "recurrence status unclear." The PSA script uses the initial PSA value before treatment to calculate the allowed time to PSA nadir (1 month for PSA values less than 50, 3 months for PSA values greater than 50, based on a serum PSA half-life of 2–3 days). If there is an invalid date, defined by a year before 1900, or a month not 1–12, or the follow-up dates are after the current date, then the script will output "Invalid follow-up date found" for that case. If for a particular case there is no (or an invalid) date of treatment, or if there is no initial PSA value then the script will output "unknown". The lack of PSA values within the initial 3 months after treatment will result in the script outputting "nadir unclear" and then using any additional PSA values to attempt a calculation of the PSA recurrence status. The PSA script orders the post-treatment PSA samples by date and takes the PSA values within 1 or 3 months of the treatment date and examines their decrease to zero (PSA nadir). These PSA values must decrease to less than 0.4, but again the user through simple script edits may modify this. Increasing post-treatment PSA values before the PSA nadir value is achieved results in the PSA script output "post prostatectomy elevated PSA." If during the 1 or 3 month post-treatment window the PSA values do not drop below 0.4, then the script outputs "nadir unclear".
Once this nadir value is achieved the date is then stored as the "PSA nadir" where no residual prostate cancer is present. After achieving PSA nadir subroutines are used to identify subsequent PSA increases over time as an indication of PSA recurrence. There are many methods for defining "PSA recurrence", with some authors using any single value above 0.2. Other authors, in particular the American Society for Theraputic Radiology and Oncology (ASTRO), have defined three consecutive increases in serum PSA post-surgery. We have chosen to integrate both systems, with PSA recurrence in the algorithm defined as a single PSA value of greater than 0.4, or a PSA value greater than 0.2 with additional subsequent increasing values. While this has been successful in our hands, the algorithm is designed such that a few simple coding changes can allow a person to alter the algorithm to suit their individual needs. As the PSA levels rise the date of PSA recurrence is determined as the date of the initial PSA rise (either the date of the single value of greater than 0.4 or the date of the PSA value greater than 0.2, before the subsequent rising PSA values) and this date is subtracted from the date of initial PSA nadir to determine the months to PSA recurrence. If there was no documented PSA nadir date then the script uses the initial treatment date as the nadir date. These time values are subsequently recorded for output. Minimum default values used for the algorithm include a single post-nadir PSA value, otherwise the output of "nadir achieved, recurrence status unknown." is provided. Thus this script can be used as a simple method for calculating PSA recurrence values on any database that tracks serum PSA levels in patients having been treated for prostate cancer.
Added output columns for each case
Sample outputs analyzed with the PSA recurrence algorithm demonstrate the calculation of PSA recurrence rates for 30 patients with prostate cancer treated by radical prostatectomy. An anonymous de-identified sample dataset of 30 patients with a range of 0 to 21 post-treatment PSA values per patient were analyzed with the PSA algorithm. Using this dataset (see supplemental file 2) the PSA script correctly calculated 14 cases that underwent PSA nadir. Of these cases 8 were without evidence of PSA recurrence, while 5 underwent PSA recurrence. In 1 case there was insufficient data to calculate PSA recurrence status after achieving PSA nadir. In 10 cases there was insufficient data to calculate PSA nadir due to a lack of PSA values within the 1 or 3 month interval after treatment, but data was available to calculate PSA recurrence status. The PSA script was not able to calculate the PSA status of 6 cases in the dataset due to missing initial PSA data (3 cases), dates (1 case) of data of any kind (2 cases). The results obtained from the PSA script was in exact agreement with a hand annotated results calculated by one of the authors (M.W.D.). In the cases where the PSA script was not able to provide a definitive result, the author was able to do no better.
The use of the PSA script was able to accurately identify patients who had undergone PSA nadir, and patients with subsequent PSA recurrence. In each of these cases the use of a uniform standard was of great value in the subsequent analysis of the outcomes data. A specific area worthy of comment includes the identification of cases with "post-treatment elevated PSA". In these cases there has been a failure to achieve PSA nadir, as defined by decreasing PSA values to less than 0.4 post-prostatectomy. Reasons why a patient may not undergo PSA nadir include the presence of residual prostate cancer within the patient. This may be due to incomplete surgical excision of tumor, spread of the tumor outside the prostate prior to surgery or radiation treatment. In addition, if residual normal prostate tissue is left within the patient after surgery, this may account for residual small but elevated PSA levels. Further evaluation of patients who fail to undergo PSA nadir may identify the potential roles of these factors in the elevated PSA values. After PSA nadir, the elevation of PSA values is indicative of tumor recurrence. The rate at which the PSA rises, or PSA velocity, has been noted to be different between local tumor recurrence and the growth of metastatic disease. This is important as the types of treatment offered to the patients (local radiation or cryotherapy vs. hormonal/chemotherapy) differ. Further modifications of this simple script should focus on improving these measurements if further clinical value is desired.
Here we have presented a simple Perl script for the evaluation of PSA status in patient datasets. Based on the current criteria for PSA nadir and recurrence, the script provides for the uniform application of PSA nadir and recurrence criteria. At the same time the script is flexible enough to allow users to change the criteria (PSA cutoff values, etc) for specific use interests and studies. It is hoped that this will facilitate the use of large patient samples for prostate cancer studies. The Perl script provided without any restrictions and may be modified for any purpose. It is readily available and is attached to this publication (appendix). While the script has been used with an associated Oracle 8 database, the script has been modified to be used with an input flat file, and as such does not need any database.
The authors would like to acknowledge the support of the NCI Co-Operative Prostate Cancer Tissue Resource (CPCTR) which led to the initiation of this study. Z.L. and M.W.D. are funded in part by NCI U01-CA86743, and Z.L. is funded in part by the MCW General Clinical Research Center Grant NIH M01-RR00058.
- Oesterling JE, Chan DW, Epstein JI, Kimball A. W., Jr., Bruzek DJ, Rock RC, Brendler CB, Walsh PC: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988, 139: 766-772.PubMedGoogle Scholar
- Chu TM, Murphy GP: What's new in tumor markers for prostate cancer?. Urology. 1986, 27: 487-491. 10.1016/0090-4295(86)90324-9.View ArticlePubMedGoogle Scholar
- Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993, 20: 713-725.PubMedGoogle Scholar
- Chodak GW, Neumann J, Blix G, Sutton H, Farah R: Effect of external beam radiation therapy on serum prostate-specific antigen. Urology. 1990, 35: 288-294.View ArticlePubMedGoogle Scholar
- Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter HB: Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology. 1993, 42: 383-389. 10.1016/0090-4295(93)90362-E.View ArticlePubMedGoogle Scholar
- Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol. 2000, 163: 1632-1642. 10.1097/00005392-200006000-00003.View ArticlePubMedGoogle Scholar
- Polascik TJ, Oesterling JE, Partin AW: Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol. 1999, 162: 293-306. 10.1097/00005392-199908000-00003.View ArticlePubMedGoogle Scholar
- Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. Jama. 1999, 281: 1598-1604. 10.1001/jama.281.17.1598.View ArticlePubMedGoogle Scholar
- Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994, 43: 649-659.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/4/8/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.